本文選題：食管癌 + 癌前病變��； 參考：《山東大學(xué)》2017年碩士論文

【摘要】：目的建立化學(xué)致癌劑4-硝基喹啉-1-氧化物(4NQO)誘導(dǎo)的KM小鼠食管癌前病變模型;通過(guò)HE染色和病理組織學(xué)檢測(cè)方法,觀察并分析沙棘干乳劑對(duì)食管癌前病變的阻斷作用。方法選取145只健康昆明小鼠,雌雄各半,隨機(jī)分為4組:A組(空白對(duì)照組)10只、B組(單純誘癌組)45只、C組(沙棘干乳劑治療組)45只、D組(全反式維甲酸陽(yáng)性對(duì)照組)45只。(1)A組:實(shí)驗(yàn)開(kāi)始第1天～24周末,正常飲食、飲蒸餾水,不施加干預(yù);B組:實(shí)驗(yàn)開(kāi)始第1天～14周,自由飲用濃度0.1g/mL的4NQO水溶液,第14周末將4NQO水溶液改為飲用蒸餾水;C組:實(shí)驗(yàn)開(kāi)始第1天～14周,自由飲用濃度O.1g/mL的4NQO水溶液,第14周末將4NQO水溶液改為飲用蒸餾水,并增加沙棘干乳劑(研究藥物)灌胃,持續(xù)至實(shí)驗(yàn)結(jié)束;D組:實(shí)驗(yàn)開(kāi)始第1天～14周,自由飲用濃度0.1g/mL的4NQO水溶液,第14周末將4NQO水溶液改為飲用蒸餾水,并增加全反式維甲酸(陽(yáng)性對(duì)照藥物)灌胃,持續(xù)至實(shí)驗(yàn)結(jié)束。(2)實(shí)驗(yàn)第10周末、第12周末、第14周末,均分別解剖A組小鼠2只、B組小鼠2只,于第14周末時(shí),病理組織學(xué)檢測(cè)結(jié)果證實(shí)模型建立成功;第19周末時(shí),分別解剖A組小鼠2只,B、C、D組各組20只;24周末時(shí),解剖各組剩余小鼠。通過(guò)HE染色和病理組織學(xué)檢測(cè)方法縱向動(dòng)態(tài)觀察4NQO誘導(dǎo)的小鼠食管上皮黏膜組織發(fā)生癌前病變的變化過(guò)程;同時(shí)橫向比較各組小鼠的食管上皮黏膜組織的增生程度,觀察并分析沙棘干乳劑對(duì)小鼠食管癌前病變的阻斷作用。結(jié)果(1)第14周末時(shí):B組5例小鼠出現(xiàn)食管上皮黏膜組織輕度異型增生3例、中度異型增生1例、重度異型增生1例,異型增生率(輕+中+重度異型增生)為100%(5/5);(2)第19周末時(shí):A、B、C、D四組同期相比,患癌率均無(wú)顯著性差異(fisher P=0.927);B、C、D三組同期相比,輕+中度異型增生率、重度異型增生+癌變率均無(wú)顯著性差異(χ~2=2.679,P0.05);(3)第24周末時(shí):C組和B組同期相比,C組患癌率明顯低于B組(χ~2=6.561,P0.05);D組與B組同期相比,D組患癌率明顯低于B組(χ~2=10.506,P0.05);C組與D組同期相比,兩組患癌率無(wú)顯著性差異(χ~2=0.739,P0.05);結(jié)論(1)通過(guò)連續(xù)14周自由飲用濃度為0.1g/mL的4NQO水溶液的方法,可成功建立KM小鼠食管癌前病變模型;(2)沙棘干乳劑對(duì)食管癌前病變有一定的阻斷作用,從而可以減緩食管癌前病變發(fā)展的進(jìn)程,防止進(jìn)一步惡變;且其阻斷作用程度與全反式維甲酸相當(dāng)。目的比較鈣離子激活氯離子通道蛋白1(anoctamin1,ANO1)、表皮生長(zhǎng)因子受體(Epidermal Growth Factor Receptor,EGFR)蛋白在小鼠不同食管上皮組織病變中的表達(dá),探討ANO1、EGFR蛋白表達(dá)與小鼠食管上皮黏膜組織病變的關(guān)系,為早期食管癌變?cè)\斷提供參考。方法應(yīng)用化學(xué)致癌劑4硝基喹琳1氧化物(4NQO)由飲水法建立小鼠食管癌前病變模型,應(yīng)用免疫組化方法檢測(cè)小鼠不同食管上皮病變中EGFR、ANO1蛋白的表達(dá)水平。結(jié)果(1)ANO1表達(dá)定位于細(xì)胞漿,其中正常組織、輕度異型增生組織、中度異型增生組織、重度異型增生組織和癌變組織中的ANO1蛋白陽(yáng)性表達(dá)率分別為 0%(0/14)、0%(0/25)、2.56%(1/39)、34.78%(8/23)和 50.00%(22/44);ANO1在癌組織中的陽(yáng)性率顯著高于正常組織(χ~2=11.278,P0.05)、輕度異型增生組織(χ~2=18.351,P0.05)及中度異型增生組織(χ~2=23.224,P0.05);ANO1在重度異型增生組織中的陽(yáng)性率顯著高于正常組織(fisher P=0.015)、輕度異型增生組織(χ~2=8.081,P0.05)及中度異型增生組織(χ~2=9.645,P0.05)。(2)EGFR表達(dá)定位于細(xì)胞漿,其中正常組織、輕度異型增生組織、中度異型增生組織、重度異型增生組織和癌變組織中的EGFR蛋白陽(yáng)性表達(dá)率分別為7.14%(1/14)、16.00%(4/25)、23.08%(9/39)、52.17%(12/23)和 59.09%(26/44);EGFR在癌組織中的陽(yáng)性率顯著高于正常組織(χ~2=11.519,P0.05)、輕度異型增生組織(χ~2=12.046,P0.05)及中度異型增生組織(χ~2=10.996,P0.05);EGFR在重度異型增生組織中的陽(yáng)性率顯著高于正常組織(fisher P=0.011)、輕度異型增生組織(X2=7.054,P0.05)及中度異型增生組織(χ~2=5.469,P0.05)。67例重度異型增生及癌變組織中,ANO1表達(dá)陽(yáng)性組中EGFR陽(yáng)性率為93.33%(28/30),ANO1 表達(dá)陰性組中 EGFR 陰性率為 72.97%(27/37),ANO1 和 EGFR的表達(dá)相關(guān)系數(shù)r=0.665,相關(guān)性具有顯著性意義(P0.05)。結(jié)論(1)ANO1在重度異型增生及癌變組織中表達(dá)特異性高,提示其參與食管癌的發(fā)生發(fā)展,并有可能成為新的食管癌藥物治療靶點(diǎn)和生物學(xué)標(biāo)記;(2)ANO1、EGFR在食管重度異型增生及癌變組織中的表達(dá)呈一定正相關(guān),兩者的雙向交互作用可能為其機(jī)制。
[Abstract]:Objective to establish a precancerous precancerous lesion model in KM mice induced by chemical carcinogen 4- nitroquinoline -1- oxide (4NQO), and to observe and analyze the blocking effect of seabuckthorn dry emulsion on precancerous lesions of the esophagus by HE staining and histopathological detection. Methods 145 healthy Kunming rats were selected and divided into 4 groups randomly: A group (blank control) Group B (group B) 45, group C (Seabuckthorn dry emulsion treatment group) 45, group D (all trans retinoic acid positive control group) 45. (1) group A: the experiment began first days to 24 weekend, normal diet, drink distilled water, no intervention; B group: the experiment began first to 14 weeks, free drinking concentration of 0.1g/mL 4NQO solution, fourteenth weekend 4NQO water solution, fourteenth weekend solution 4NQO water solution. The liquid was changed to distilled water for drinking. Group C: the experiment started first to 14 weeks, the free drinking concentration of 4NQO solution of O.1g/mL was free, the 4NQO solution was changed into drinking distilled water at the end of the fourteenth week, and the Seabuckthorn dry emulsion was added to the stomach and continued to the end of the experiment; group D: the experiment began first to 14 weeks, the free drinking concentration of 0.1g/mL 4NQO solution, fourteenth weeks At the end, the 4NQO water solution was changed into drinking distilled water, and all trans retinoic acid (positive control drugs) was added to the stomach and continued to the end of the experiment. (2) 2 mice in group A and 2 mice in group B were dissected respectively at the weekend of the experiment, twelfth weekend and fourteenth weekend. At the end of the fourteenth week, the pathological histological examination confirmed the success of the model; nineteenth weekend, respectively, respectively. 2 mice in group A, 20 rats in group B, C and D were dissected. At the 24 weekend, the remaining mice were dissected. The changes in the precancerous lesion of the esophageal epithelium induced by 4NQO were observed longitudinally by HE staining and histopathological detection, and the degree of proliferation of esophageal epithelial tissue in each group was compared and observed and observed. The blocking effect of seabuckthorn dry emulsion on precancerous lesions of the esophagus in mice was analyzed. Results (1) at the end of fourteenth weeks, 5 mice in group B showed mild dysplasia in esophageal epithelium, 1 cases of moderate dysplasia, 1 severe dysplasia, 100% (5/5) with the rate of dysplasia (mild + severe atypical growth), and (2) nineteenth weekend: A, B, C, and D four group of four phase There was no significant difference in the rate of cancer (Fisher P=0.927), and there was no significant difference in the rate of light + moderate dysplasia, severe dysplasia and cancer (P0.05) in the three groups of B, C and D. (3) at the twenty-fourth weekend, the cancer rate in the C and B groups was significantly lower than that in the B group (x ~2=6.561,). Compared with group B (x ~2=10.506, P0.05), there was no significant difference between the two groups in the C group and the D group (x ~2=0.739, P0.05), and (1) the esophageal precancerous lesion model of KM mice could be successfully established by the method of 4NQO aqueous solution of 0.1g/mL for 14 weeks of free drinking, and (2) the Seabuckthorn dry emulsion had a certain blocking effect on the precancerous lesions of the esophagus. It can be used to slow down the progression of precancerous lesions of the esophagus and prevent further malignant change; and its blocking effect is equivalent to all trans retinoic acid. Objective to compare calcium ion activated chloride channel protein 1 (anoctamin1, ANO1), Epidermal Growth Factor Receptor, EGFR protein in different esophageal epithelial tissues in mice The relationship between the expression of ANO1, EGFR protein and the pathological changes of esophageal epithelial mucosa in mice was discussed in order to provide reference for the diagnosis of early esophageal carcinogenesis. Methods the chemical carcinogen 4 nitroquinine 1 oxide (4NQO) was used to establish the precancerous precancerous lesion model of mice by drinking water method, and the different esophageal epithelial diseases in mice should be detected by immunohistochemical method. The expression level of EGFR, ANO1 protein. Results (1) the expression of ANO1 was located in the cytoplasm. The positive expression rates of ANO1 protein in normal tissue, mild dysplasia, severe dysplasia, severe dysplasia and cancerous tissues were 0% (0/14), 0% (0/25), 2.56% (1/39), 34.78% (8/23) and 50% (22/44); ANO1 in the cancer group. The positive rate in the fabric was significantly higher than that of normal tissue (x ~2=11.278, P0.05), mild dysplasia (x ~2=18.351, P0.05) and moderate dysplasia (x ~2=23.224, P0.05). The positive rate of ANO1 in severe dysplasia was significantly higher than that of normal tissue (Fisher P =0.015), and the mild dysplasia (chi ~2=8.081, P0.05) and moderate atypia were increased. (x ~2=9.645, P0.05). (2) the expression of EGFR was located in the cytoplasm. The positive rates of EGFR protein expression in normal tissue, mild dysplasia, severe dysplasia, severe dysplasia and cancerous tissues were 7.14% (1/14), 16% (4/ 25), 23.08% (9/39), 52.17% (12/23) and 59.09% (26/44); EGFR was in the cancer tissue. The positive rate was significantly higher than that of normal tissue (x ~2=11.519, P0.05), mild dysplasia (x ~2=12.046, P0.05) and moderate dysplasia (x ~2=10.996, P0.05). The positive rate of EGFR in severe dysplasia was significantly higher than that of normal tissue (Fisher P=0.011), mild dysplasia (X2=7.054, P0.05) and moderate dysplasia (P0.05). The positive rate of EGFR in ANO1 expression positive group was 93.33% (28/30), EGFR negative rate in ANO1 negative group was 72.97% (27/37) in ANO1 negative group, and the correlation coefficient of ANO1 and EGFR was significant (1) in severe dysplasia and cancerous tissue in.67 negative group.67. It has high expression specificity, suggesting that it participates in the development of esophageal cancer and may become a new target for the treatment of esophageal cancer and biological markers. (2) ANO1, EGFR is positively correlated with the expression of severe dysplasia and cancerous tissues of the esophagus, and the two-way interaction between them may be the mechanism.

【學(xué)位授予單位】：山東大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R735.1

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 趙娜;董坤;豐平;王學(xué)江;;骨髓間充質(zhì)干細(xì)胞在肝癌前病變形成過(guò)程中的分化[J];中國(guó)病理生理雜志;2010年10期

2 馬益如;;什么叫癌前病變?常見(jiàn)的癌前病變有哪些?應(yīng)如何處理?[J];廣西赤腳醫(yī)生;1976年09期

3 周磊;癌前病變治療研究進(jìn)展[J];湛江醫(yī)學(xué)院學(xué)報(bào);1990年Z1期

4 ;何謂癌前病變?[J];農(nóng)民致富之友;1995年03期

5 柴可夫;胃粘膜癌前病變的中醫(yī)藥防治研究[J];長(zhǎng)春中醫(yī)學(xué)院學(xué)報(bào);2000年02期

6 賈建華,潘祖健;淺談中醫(yī)對(duì)胃癌前病變的認(rèn)識(shí)[J];黑龍江中醫(yī)藥;2001年01期

7 覃揚(yáng)達(dá),梁建平;喉的癌前病變[J];中國(guó)醫(yī)學(xué)文摘(老年醫(yī)學(xué));2004年02期

8 劉增巍,張星星;中藥治療胃癌前病變療效的薈萃分析[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2005年21期

9 林興,黃云超;肺癌癌前病變的研究進(jìn)展[J];中國(guó)肺癌雜志;2005年02期

10 宋磊;張濤源;;喉的癌前病變[J];山西醫(yī)藥雜志;2006年08期

相關(guān)會(huì)議論文 前10條

1 豐平;徐大鵬;劉樹(shù)紅;李向利;文朝陽(yáng);;槲芪散防治大鼠肝癌前病變的病理形態(tài)研究[A];中國(guó)病理生理學(xué)會(huì)第九屆全國(guó)代表大會(huì)及學(xué)術(shù)會(huì)議論文摘要[C];2010年

2 李慧臻;;胃癌前病變的臨床及實(shí)驗(yàn)研究近況[A];中國(guó)中西醫(yī)結(jié)合學(xué)會(huì)第十六次全國(guó)消化系統(tǒng)疾病學(xué)術(shù)研討會(huì)論文匯編[C];2004年

3 張萬(wàn)岱;姚永莉;梁衛(wèi)江;;胃癌前病變的診治進(jìn)展[A];中國(guó)中西醫(yī)結(jié)合第十九次全國(guó)消化病學(xué)術(shù)會(huì)議暨國(guó)家級(jí)中西醫(yī)結(jié)合消化疾病新進(jìn)展學(xué)習(xí)班論文匯編[C];2007年

4 李佩玲;;婦癌癌前病變的診治進(jìn)展[A];東北三省第四屆婦產(chǎn)科學(xué)術(shù)會(huì)議論文匯編[C];2008年

5 唐旭東;王萍;李振華;李保雙;;關(guān)于胃癌前病變療效評(píng)價(jià)的幾點(diǎn)思考[A];中華中醫(yī)藥學(xué)會(huì)第二十一屆全國(guó)脾胃病學(xué)術(shù)交流會(huì)暨2009年脾胃病診療新進(jìn)展學(xué)習(xí)班論文匯編[C];2009年

6 梁健;鄧鑫;吳發(fā)勝;李龍華;;胃寧顆粒治療胃癌前病變的臨床研究[A];第二十四屆全國(guó)中西醫(yī)結(jié)合消化系統(tǒng)疾病學(xué)術(shù)會(huì)議專題報(bào)告及論文集[C];2012年

7 姚樹(shù)坤;;消化道癌前病變干預(yù)策略的思考[A];第二十二屆全國(guó)中西醫(yī)結(jié)合消化系統(tǒng)疾病學(xué)術(shù)會(huì)議暨消化疾病診治進(jìn)展學(xué)習(xí)班論文匯編[C];2010年

8 張萬(wàn)岱;姚永莉;梁衛(wèi)江;;胃癌前病變的診治進(jìn)展[A];2008全國(guó)消化腫瘤新技術(shù)治療研討會(huì)論文匯編[C];2008年

9 杜艷茹;;劉啟泉教授從毒瘀論治胃癌前病變[A];中華中醫(yī)藥學(xué)會(huì)脾胃病分會(huì)第十九次全國(guó)脾胃病學(xué)術(shù)交流會(huì)論文匯編[C];2007年

10 陳樂(lè)真;;子宮內(nèi)膜癌前病變的研究新進(jìn)展[A];中華醫(yī)學(xué)會(huì)第九次全國(guó)婦科腫瘤學(xué)術(shù)會(huì)議論文匯編[C];2006年

相關(guān)重要報(bào)紙文章 前10條

1 主任醫(yī)師 徐榕;癌前病變不等于癌[N];衛(wèi)生與生活報(bào);2008年

2 指導(dǎo)專家 河北省秦皇島市腫瘤醫(yī)院放療科 趙成全 主任醫(yī)師 記者 朱楊;警惕六類癌前病變[N];醫(yī)藥導(dǎo)報(bào);2007年

3 主任醫(yī)師 彭丹;別被癌前病變嚇著[N];衛(wèi)生與生活報(bào);2009年

4 吳志;癌前病變不可怕[N];衛(wèi)生與生活報(bào);2009年

5 上海龍華醫(yī)院腫瘤科 王菊勇 副研究員;走近癌前病變[N];上海中醫(yī)藥報(bào);2010年

6 孟磊;癌前病變就是癌嗎[N];中國(guó)醫(yī)藥報(bào);2003年

7 張中橋;別拿“不死的癌癥”嚇唬人[N];中國(guó)中醫(yī)藥報(bào);2006年

8 方萍邋馮立中;激光治療阻斷喉部癌前病變[N];健康報(bào);2007年

9 秦皇島市腫瘤醫(yī)院主任醫(yī)師 趙成會(huì);癌前病變會(huì)發(fā)展成癌嗎?[N];河北科技報(bào);2010年

10 本報(bào)記者 曹玉祥;千萬(wàn)要抓緊癌前病變防治(一)[N];醫(yī)藥養(yǎng)生保健報(bào);2009年

相關(guān)博士學(xué)位論文 前10條

1 王峰;乳腺癌前病變大鼠動(dòng)物模型的建立、評(píng)價(jià)及其發(fā)生機(jī)制的初步研究[D];山東大學(xué);2015年

2 曾進(jìn)浩;健脾化瘀解毒方調(diào)控Wnt通路介導(dǎo)胃癌前病變大鼠Lgr5+細(xì)胞的機(jī)制研究[D];廣州中醫(yī)藥大學(xué);2016年

3 胡偉玲;胃癌前病變精準(zhǔn)監(jiān)測(cè)和癌變有效逆轉(zhuǎn)診療系統(tǒng)數(shù)字化建設(shè)[D];浙江大學(xué);2014年

4 楊應(yīng)成;肝臟癌前病變的發(fā)生機(jī)制研究[D];第二軍醫(yī)大學(xué);2016年

5 李彤;馬兜鈴酸-I致胚胎干細(xì)胞衍生肝樣組織癌前病變?cè)u(píng)價(jià)模型建立[D];浙江大學(xué);2017年

6 張秀娟;中藥通過(guò)線粒體途徑治療胃癌前病變大鼠的實(shí)驗(yàn)研究[D];遼寧中醫(yī)藥大學(xué);2010年

7 宮媛;骨髓間充質(zhì)干細(xì)胞移植對(duì)大鼠胃癌前病變模型的干預(yù)和機(jī)制的初步探討[D];中國(guó)人民解放軍醫(yī)學(xué)院;2013年

8 王賢文;鼻咽癌前病變證素計(jì)量辯證規(guī)范及其相關(guān)蛋白質(zhì)組學(xué)基礎(chǔ)研究[D];湖南中醫(yī)藥大學(xué);2009年

9 王垂杰;阻癌胃泰治療胃癌前病變脾虛血瘀證療效機(jī)制的實(shí)驗(yàn)研究[D];黑龍江中醫(yī)藥大學(xué);2003年

10 張磊;RB熒光光譜法輔助診斷口腔癌前病變的實(shí)驗(yàn)研究[D];哈爾濱醫(yī)科大學(xué);2012年

相關(guān)碩士學(xué)位論文 前10條

1 韓旭;人食管鱗癌癌前病變基因及相關(guān)蛋白表達(dá)變化的研究[D];北京協(xié)和醫(yī)學(xué)院;2015年

2 韓利霞;基于中藥方劑配伍機(jī)理的中藥有效成分在食管癌前病變進(jìn)程中的免疫調(diào)節(jié)作用[D];河北醫(yī)科大學(xué);2015年

3 左學(xué)勇;食管早癌及癌前病變內(nèi)鏡黏膜下剝離術(shù)前后病理差異分析[D];蘇州大學(xué);2015年

4 張亞寧;葛仙米對(duì)二乙基亞硝胺誘發(fā)小鼠肝臟癌前病變的干預(yù)作用研究[D];河南師范大學(xué);2015年

5 孫科;異常糖鏈糖蛋白在常見(jiàn)消化道癌前病變中的表達(dá)及意義[D];新疆醫(yī)科大學(xué);2015年

6 張露;芪竹參草湯治療慢性萎縮性胃炎癌前病變的臨床研究[D];南京中醫(yī)藥大學(xué);2016年

7 朱順其;經(jīng)內(nèi)鏡黏膜下剝離術(shù)治療食管早癌及癌前病變的預(yù)后及影響因素[D];中國(guó)人民解放軍醫(yī)學(xué)院;2016年

8 劉玉丹;5,2',4'-三羥基-6,7,5'-三甲氧基黃酮通過(guò)氧化應(yīng)激和內(nèi)質(zhì)網(wǎng)應(yīng)激反應(yīng)抑制大鼠肝臟癌前病變作用的研究[D];延邊大學(xué);2015年

9 王偉;基于“脾虛毒損胃絡(luò)”假說(shuō)應(yīng)用健脾消毒飲治療慢性萎縮性胃炎癌前病變的臨床研究[D];山東中醫(yī)藥大學(xué);2016年

10 覃二元;阿司匹林對(duì)于胃黏膜癌前病變根除HP后胃黏膜病理變化的影響[D];南華大學(xué);2016年

，

本文編號(hào)：1802521